PepGen (PEPG) Expected to Release Earnings on Wednesday

PepGen (NASDAQ:PEPG) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect PepGen to announce earnings of ($0.27) per share for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

PepGen (NASDAQ:PEPG) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. On average, analysts expect PepGen to post ($1.11) EPS for the current fiscal year and ($1.27) EPS for the next fiscal year.

PepGen Price Performance

PEPG stock traded down $0.01 on Wednesday, reaching $2.45. 64,352 shares of the company traded hands, compared to its average volume of 1,023,380. The company has a market cap of $169.48 million, a P/E ratio of -1.91 and a beta of 2.02. PepGen has a one year low of $1.31 and a one year high of $7.80. The firm has a fifty day simple moving average of $2.72 and a 200-day simple moving average of $3.04.

Analysts Set New Price Targets

Several brokerages recently issued reports on PEPG. Wall Street Zen downgraded PepGen from a “hold” rating to a “sell” rating in a research note on Saturday, October 10th. Weiss Ratings upgraded shares of PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd. Finally, HC Wainwright reaffirmed a “buy” rating on shares of PepGen in a research note on Wednesday, September 9th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $11.40.

PepGen Company Profile

PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.